Human medicines European public assessment report (EPAR): Erleada, apalutamide, Prostatic Neoplasms, Date of authorisation: 14/01/2019, Revision: 10, Status: Authorised
Erleada is a cancer medicine used to treat men with cancer of the prostate (a gland of the male reproductive system).
It is used when the cancer is not responding to treatments that lower testosterone levels (castration resistant) and is at high risk of spreading to other parts of the body. It is also used when the cancer has spread to other parts of the body (metastatic) but responds to treatment that lowers testosterone levels (hormone sensitive). Erleada is used in combination with a treatment called androgen deprivation therapy.
Erleada contains the active substance apalutamide.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
